Pros and Cons of Retatrutide: Benefits, Side Effects, and UK Status

The pros and cons of retatrutide are attracting growing attention as this investigational triple receptor agonist moves through clinical trials for obesity and type 2 diabetes. Developed by Eli Lilly, retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors, a mechanism that distinguishes it from existing approved therapies such as semaglutide and tirzepatide. Early Phase 2 data have generated considerable scientific interest, but retatrutide remains unapproved in the UK as of mid-2025. This article outlines what is currently known about its potential benefits, side effects, and regulatory status to help readers make informed decisions.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational once-weekly injectable drug that simultaneously activates GLP-1, GIP, and glucagon receptors, a triple-agonist mechanism designed to reduce appetite, enhance insulin secretion, and increase energy expenditure beyond what single or dual agonists achieve.

Retatrutide is an investigational injectable medication being developed by Eli Lilly as a potential treatment for obesity and type 2 diabetes.^[1][2] It belongs to a novel class of drugs known as triple receptor agonists, distinguishing it from earlier-generation weight-loss medications. Specifically, retatrutide simultaneously activates three incretin and metabolic hormone receptors:

• GLP-1 (glucagon-like peptide-1) receptor – which reduces appetite and slows gastric emptying^[6][7]

• GIP (glucose-dependent insulinotropic polypeptide) receptor – which enhances insulin secretion and may improve fat metabolism^[9][10]

• Glucagon receptor – which may increase energy expenditure and could promote hepatic fat metabolism

This triple-action mechanism sets retatrutide apart from existing approved therapies such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GLP-1/GIP agonist). By engaging all three pathways simultaneously, retatrutide is designed to produce a more pronounced effect on body weight and metabolic health than single or dual agonists, though direct head-to-head comparative trials have not yet been conducted.

The glucagon receptor component is particularly noteworthy. Whilst glucagon typically raises blood glucose, early Phase 2 trial data suggest that, when combined with GLP-1 receptor activation, its net effect may include increased calorie burning and a potential reduction in liver fat, without causing clinically significant rises in blood sugar. These are exploratory signals from limited early-phase data and should not be regarded as established clinical effects; Phase 3 confirmation is required before any firm conclusions can be drawn.

Retatrutide is administered as a once-weekly subcutaneous injection, similar in delivery to other medicines in this class. As of mid-2025, it remains under clinical investigation and has not received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA). Readers should check the MHRA and EMA websites for the most current status, as this may change. Retatrutide should only be used within the context of authorised clinical trials.

Potential Benefits of Retatrutide

Phase 2 trial data reported approximately 24% mean body weight reduction over 48 weeks at the highest dose, alongside improvements in HbA1c, waist circumference, and lipid profiles, though Phase 3 confirmation is required before firm conclusions can be drawn.

Early-phase clinical trial data for retatrutide have generated considerable interest within the medical and scientific community, primarily due to the scale of weight loss observed in participants. In a Phase 2 randomised controlled trial published in the New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023), adults with obesity (without type 2 diabetes) who received the highest dose of retatrutide (12 mg weekly) achieved a mean body weight reduction of approximately 24% over 48 weeks. This figure comes from a relatively small Phase 2 study (n=338 across all dose groups); discontinuation rates and baseline characteristics should be considered when interpreting this result. Results from larger Phase 3 trials are needed before firm conclusions can be drawn. Direct comparisons with semaglutide or tirzepatide should be interpreted with caution, as no head-to-head trials have been conducted.

Beyond weight reduction, the same trial reported several additional metabolic outcomes as secondary or exploratory endpoints:

• Improved glycaemic control – reductions in HbA1c levels were observed in participants with type 2 diabetes in a separate Phase 2 cohort^[3][4]

• Reduced waist circumference – suggesting a decrease in visceral (abdominal) fat, which is associated with cardiovascular risk; reported as a secondary endpoint in the NEJM 2023 paper

• Improvements in lipid profiles – including reductions in triglycerides, reported as an exploratory endpoint in the same trial

• Potential signal for benefit in metabolic-associated steatotic liver disease (MASLD) – based on the glucagon receptor's proposed role in hepatic fat metabolism; this remains an exploratory finding requiring further investigation

These metabolic outcomes are promising but should be regarded as hypothesis-generating at this stage. For patients with obesity-related comorbidities — such as hypertension, dyslipidaemia, or fatty liver disease — these combined effects could represent a clinically meaningful advance if confirmed in Phase 3 data. NICE guidance on obesity management (including NG246) recognises that sustained weight loss can significantly reduce the risk of type 2 diabetes, cardiovascular disease, and musculoskeletal problems.^[11]

Long-term cardiometabolic safety data and dedicated cardiovascular outcome trial results are not yet available for retatrutide. These data are important for a full understanding of the drug's benefit-risk profile and will be central to any future regulatory assessment. Conclusions about retatrutide's full benefit profile should therefore remain cautious at this stage.

Known Side Effects and Safety Concerns

The most common side effects are gastrointestinal, including nausea, vomiting, and diarrhoea; clinically important concerns include elevated resting heart rate, pancreatitis risk, gallbladder disease, and thyroid C-cell precautions consistent with the GLP-1 drug class.

As with other medicines in the incretin-based drug class, retatrutide is associated with a range of side effects, the majority of which relate to the gastrointestinal system. In Phase 2 trial data, the most commonly reported adverse effects included:

• Nausea (reported in a significant proportion of participants, particularly during dose escalation)

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite (which, whilst contributing to weight loss, can occasionally be excessive)

These effects were generally described as mild to moderate in severity and tended to diminish over time as the body adjusted to the medication. Dose escalation protocols — where the dose is gradually increased over several weeks — are typically used to minimise gastrointestinal discomfort.

Patients experiencing severe or persistent vomiting or diarrhoea should be aware of the risk of dehydration and acute kidney injury (AKI). If you are unable to keep fluids down, you should seek prompt medical attention.

Of greater clinical significance are potential safety concerns that require further investigation in larger trials:

• Heart rate elevation – glucagon is known to have chronotropic effects, and increases in resting heart rate were observed in some trial participants; this warrants careful monitoring, particularly in individuals with pre-existing cardiac conditions

• Hypoglycaemia – whilst retatrutide alone has a low intrinsic risk of hypoglycaemia, people with type 2 diabetes who are also taking insulin or sulfonylureas face an increased risk; healthcare professionals should review concomitant diabetes medicines before and during treatment

• Delayed gastric emptying – as with other GLP-1-based therapies, retatrutide may slow gastric emptying; for most oral medicines this is unlikely to be clinically meaningful, but patients taking medicines with a narrow therapeutic index (such as certain anticoagulants or thyroid hormones) should discuss this with their healthcare professional, who can advise on monitoring or timing of doses

• Pancreatitis – severe, persistent abdominal pain, particularly pain radiating to the back and accompanied by vomiting, should be assessed promptly; patients with a history of pancreatitis should discuss this with their healthcare professional before starting treatment

• Thyroid C-cell findings – GLP-1 receptor agonists have been associated with thyroid C-cell tumours in rodent studies; a direct causal link in humans has not been established. UK SmPCs for medicines in this class (such as the Mounjaro SmPC) list this as a precaution rather than a contraindication. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should discuss this precaution with their healthcare professional before using any medicine in this class

• Gallbladder disease – rapid weight loss can increase the risk of gallstones and gallbladder inflammation^[25][26]

• Diabetic retinopathy – rapid improvement in glycaemic control has been associated with worsening of diabetic retinopathy in people with pre-existing disease; this is a class-relevant caution that should be discussed with a healthcare professional^[18][19]

• Pregnancy and breastfeeding – retatrutide should not be used during pregnancy or breastfeeding. As safety data in pregnancy are not available, women of childbearing potential should use effective contraception during treatment. A washout period before planned pregnancy should be discussed with a healthcare professional

Patients experiencing severe or persistent abdominal pain, signs of an allergic reaction, or significant changes in heart rate should seek prompt medical advice.

Reporting side effects: If you are taking retatrutide outside a clinical trial and experience a suspected side effect, you can report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. If you are participating in a clinical trial, suspected side effects should be reported to the trial team or study sponsor in accordance with the trial protocol.

Current Availability and Regulatory Status in the UK

Retatrutide is not approved for clinical use in the UK as of mid-2025 and has no MHRA or EMA marketing authorisation; it is available only within authorised clinical trials, with NHS access dependent on future regulatory and NICE approval.

As of mid-2025, retatrutide is not approved for clinical use in the United Kingdom. It has not received a marketing authorisation from the MHRA, nor has it been granted approval by the EMA. The drug remains in active clinical development, with Phase 3 trials currently underway evaluating retatrutide's efficacy and safety across broader populations, including individuals with obesity, type 2 diabetes, and cardiovascular disease. Readers should verify the current status of these trials via ClinicalTrials.gov or the EU Clinical Trials Register, as trial details and regulatory status may change.

In the UK, the regulatory pathway for new medicines requires the MHRA to assess comprehensive evidence of safety, efficacy, and quality before granting a marketing authorisation. Following any potential approval, NICE would then evaluate the drug's cost-effectiveness to determine whether it should be recommended for use within the NHS. NHS availability would also depend on national commissioning arrangements, local Integrated Care Board (ICB) decisions, and specialist weight-management pathway criteria, in addition to any NICE recommendation. Given the costs typically associated with injectable weight-management therapies and existing NHS prescribing frameworks, access — if approved — may initially be limited to specific patient groups meeting defined clinical criteria, as has been the case with other agents in this class.

For patients currently seeking weight management support, the NHS offers a range of evidence-based options. NICE-recommended pharmacological treatments currently include:

• Orlistat – available on NHS prescription

• Semaglutide (Wegovy®) – approved by the MHRA for chronic weight management and subject to a phased NHS rollout, with eligibility criteria defined by NICE technology appraisal^[21][22]

• Tirzepatide (Mounjaro®) – holds MHRA authorisation for both the treatment of type 2 diabetes and for chronic weight management in adults; NHS access for weight management is subject to NICE technology appraisal guidance and commissioning decisions

Patients should note that Mounjaro® is the UK-authorised brand of tirzepatide; prescribing should follow the relevant licensed indication and applicable NICE guidance.

Patients interested in retatrutide may wish to explore participation in clinical trials. The NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) provides information on trials recruiting in the UK and can help identify whether any retatrutide studies are open to participants. Eligibility criteria apply to all trials.

Anyone considering weight management treatment should consult their GP or a specialist obesity service in the first instance. NHS specialist weight management services can provide access to multidisciplinary support, including dietary, behavioural, and pharmacological interventions. Self-prescribing or obtaining unregulated medicines online carries significant safety risks and is strongly discouraged.

Scientific References

1. Triple–Hormone-Receptor Agonist Retatrutide for Obesity (Jastreboff et al.).
2. Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
3. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial.
4. Retatrutide-A Game Changer in Obesity Pharmacotherapy.
5. Effects of retatrutide on body composition in people with type 2 diabetes.
6. The multifaceted role of GLP-1 in metabolic disorders, chronic inflammation, and aging: Mechanisms and therapeutic potential.
7. The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review.
8. Gut Hormones and Inflammatory Bowel Disease.
9. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1.
10. Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice.
11. Overweight and obesity management (NG246).
12. MHRA updates guidance for GLP-1 prescribers and patients.
13. Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review.
14. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception.
15. Glucagon-like Peptide-1 Receptor Agonists and Reproductive Health: Current Evidence and Clinical Implications.
16. Approach to the Patient With Thyroid Nodules: Considering GLP-1 Receptor Agonists.
17. Suppressed thyroid stimulating hormone levels after initiation of a subcutaneous GLP-1 receptor agonist in a post-thyroidectomy patient managed with levothyroxine: case report.
18. The impact of improved glycaemic control with GLP-1 receptor agonists on diabetic retinopathy.
19. GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications.
20. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review.
21. Single-dose 7.2mg semaglutide (Wegovy) pen approved to treat adult patients with obesity.
22. Semaglutide for managing overweight and obesity (TA875).
23. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
24. Four-dose Mounjaro KwikPen approved by MHRA for diabetes and weight management.
25. GLP-1 receptor agonists and gallbladder disease risk.
26. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases.
27. Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database.

Frequently Asked Questions